Abstract: Novel peptides of the formula: ##STR1## wherein: A, A' and A" are each independently Gly, D-Ala, D-Leu, or D-Trp, wherein A may optionally be N-alkylated or N-acylated;B is Pro, .DELTA..sup.3 -Pro, Thz, or diMeThz;C and C' are each independently Thr, Ser, Val, or alloThr;D is Glu, Gln, Asp, or Asn;R is hydrogen, or is lower alkyl or lower acyl, substituted for one of the hydrogens on the .epsilon.-amino group of the lysyl residue;X is Cys, Ala, ABU, or Cys(Me); andY is selected from the group consisting of hydroxy, Pro, Pro-Leu, and Pro-Leu-Met, -NH.sub.2, ProNH.sub.2, Pro-LeuNH.sub.2 and Pro-leu-MetNH.sub.2 ;and the pharmaceutically acceptable salts thereof, are useful for increasing immunologic competence. Methods for preparation of the peptides are also described.

Abstract: Nonapeptide and decapeptide analogs of LH-RH of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein: V is tryptophyl, phenylalanyl or 3-(1-naphthyl)-L-alanyl;W is tyrosyl, phenylalanyl or 3-(1-pentafluorophenyl)-L-alanyl;X is a D-amino acid residue of the formula: ##STR2## wherein R is a heterocyclic aryl containing radical selected from the group consisting of radicals represented by the following structural formulas: ##STR3## wherein A and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine, and bromine, and G is selected from the group consisting of oxygen, nitrogen, and sulfur;Y is leucyl, isoleucyl, nor-leucyl or N-methyl-leucyl;Z is glycinamide or --NH--R.sup.1, wherein:R.sup.1 is lower alkyl, cycloalkyl, fluoro lower alkyl or ##STR4## wherein R.sup.2 is hydrogen or lower alkyl,are disclosed. These compounds exhibit potent LH-RH agonist properties.

Abstract: The 2,3-diesters of 6-substituted-2,3-dihydroxy-1,4-naphthoquinones exhibit useful anti-psoriatic activity in mammals.

Abstract: Nonapeptide and decapeptide analogs of LH-RH of the formula(pyro)Glu-His-V-Ser-W-X-Y-Arg-Pro-Z (I)and the pharmaceutically acceptable salts thereof wherein:V is tryptophyl, phenylalanyl or 3-(1-naphthyl)-L-alanyl;W is tyrosyl, phenylalanyl or 3-(1-pentafluorophenyl)-L-alanyl;X is a D-amino acid residue ##STR1## wherein R is (a) a carbocyclic aryl-containing radical selected from the group consisting of naphthyl, anthryl, fluorenyl, phenanthryl, biphenylyl, benzhydryl and phenyl substituted with three or more straight chain lower alkyl groups; or(b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl and adamantyl;Y is leucyl, isoleucyl, nor-leucyl or N-methyl-leucyl;Z is glycinamide or --NH--R.sup.1, whereinR.sup.1 is lower alkyl, cycloalkyl, fluoro lower alkyl or ##STR2## wherein R.sup.2 is hydrogen or lower alkyl,are disclosed.

Abstract: Psoriasis in mammals is relieved by topically administering substituted naphthaquinones of the formula: ##STR1## where R.sup.1 and R.sup.2 are the same or different and are hydrogen, hydroxy, alkoxy or acylamino and R.sup.3 is hydrogen, halo, cyano or alkoxy with the proviso that R.sup.1 and R.sup.2 are not both hydrogen.

Abstract: This application relates to novel immunological adjuvant compounds of the formula: ##STR1## wherein each of R and R.sup.1 are the same or different and are hydrogen or an acyl radical; R.sup.2 is an unsubstituted or substituted alkyl radical, or an unsubstituted or substituted aryl radical; R.sup.6 is an alkyl radical X is an aminoacyl moiety; and Y is D-isoasparagine or D-isoglutamine.

Abstract: This application relates to novel immunological adjuvant compounds of the formula: ##STR1## wherein each of R and R.sup.1 are the same or different and are hydrogen or an acyl radical; R.sup.2 is an unsubstituted or substituted alkyl radical, or an unsubstituted or substituted aryl radical; X is an aminoacyl moiety; and Y is D-isoasparagine or D-isoglutamine.

Abstract: A novel class of intermediates from which a variety of uronic acid nucleosides can be produced, said class being represented by the following formula: ##SPC1##WhereR.sub.1 and R.sub.2 are lower alkyl radicals having one to six carbon atoms, or phenyl radicals;R.sub.3 is a lower alkyl radical having one to four carbon atoms; and the wavy line at the 5' position indicates both the 5'-D-allo and 5'-L-talo epimers.A process for producing these intermediates is described. A process for converting these intermediates to uronic acid nucleosides having the following formula: ##SPC2##WhereB is a pyrimidine or purine base, is also described.Novel uronic acid nucleosides, having structures falling within the general formula given above, are identified.